LONDON (Alliance News) - 4D Pharma PLC Friday said that it has commenced dosing in a phase one clinical trial for the treatment of irritable bowel syndrome.
The pharmaceutical company said that the clinical trial will assess the safety and tolerability of Blautix in a number of healthy volunteers with IBS. In addition, clinical symptoms and biomarkers relevant to the mechanism action of Blautix will be assessed, with the trial expected to be completed in late 2015.
According to 4D Pharma, an estimated 10% to 15% of the population have IBS, but there are currently few approved treatment options for the condition.
"Having obtained regulatory and ethical approval for the Blautix clinical trial, dosing of the first subjects represents an important milestone in the development of the Live Biotherapeutics class. Blautix has been designed to treat the underlying cause of IBS, rather than just the symptoms and we look forward to assessing its effects in a clinical setting," Chief Scientific Officer Alex Stevenson said in a statement.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
